OpenNashEarnings

Pharmaceuticals · SIX: ROG

Roche earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 22 Jul 2027

Investor relations ↗KPIs as CSV

Latest: Q3 2026

Roche advanced up to 20 potential new medicines toward 2030 while FDA Priority Reviews for fenebrutinib and giredestrant set up multiple late-2026 launches in multiple sclerosis and breast cancer.

Roche's growth came from a broad base of medicines for severe disease: Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo led. Ocrevus's subcutaneous version now makes up over 20% of Ocrevus volume, and Vabysmo has reached about 1.5m patients. FDA approvals arrived for Tecentriq in colon cancer and Enspryng in thyroid eye disease, and Diagnostics won clearance for the Elecsys pTau217 Alzheimer's blood test.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗

Quarters

KPI history